Get started
Author

Farid El Hajbi

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
2021 · Thierry Conroy, Jean-François Bosset, et al. · The Lancet Oncology · 1,385
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
2022 · Thierry Conroy, Florence Castan, et al. · JAMA Oncology · 375
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study
2018 · Stefano Kim, Eric François, et al. · The Lancet Oncology · 149
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial
2019 · Pascal Hammel, Portales Fabienne, et al. · European Journal of Cancer · 114
PDF
Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
2021 · Ian Chau, Yuichiro Doki, et al. · Journal of Clinical Oncology · 99
Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial
2018 · Alice Bernard-Tessier, Emmanuelle Jeannot, et al. · Clinical Cancer Research · 99
Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study
2011 · D. Laharie, S. Mesli, et al. · Alimentary Pharmacology & Therapeutics · 86
PDF
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results
2017 · T. Aparicio, O. Bouché, et al. · Annals of Oncology · 78
PDF
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma ( CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
2024 · Ken Kato, Yuichiro Doki, et al. · Cancer Medicine · 68
PDF
Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis
2016 · C. Baldini, A. Escande, et al. · Pancreatology · 45
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
2016 · Mathieu Messager, Xavier Mirabel, et al. · BMC Cancer · 42
PDF
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer
2018 · T. Aparicio, O. Bouché, et al. · European Journal of Cancer · 40
LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)
2021 · N. Girard, J. Mazieres, et al. · Annals of Oncology · 38
Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma
2020 · Stefano Kim, Aurélia Meurisse, et al. · Therapeutic Advances in Medical Oncology · 33
PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
2025 · Michel Ducreux, Romain Desgrippes, et al. · Journal of Clinical Oncology · 32
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
2024 · Stefano Kim, Francois Ghiringhelli, et al. · The Lancet Oncology · 30
Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma
2015 · Bertrand Brieau, Céline Lepère, et al. · Medicine · 30
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial
2020 · Julien Taïeb, Thierry André, et al. · Digestive and Liver Disease · 26
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
2020 · Stefano Kim, Bruno Buecher, et al. · BMC Cancer · 26
PDF
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
2019 · A. Adenis, J. Bennouna, et al. · European Journal of Cancer · 24
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
2017 · Stefano Kim, Marine Jary, et al. · BMC Cancer · 24
PDF
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR)
2023 · Julie Veziant, Olivier Bouché, et al. · Digestive and Liver Disease · 17
PDF
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
2021 · Camille Evrard, Christophe Louvet, et al. · Digestive and Liver Disease · 17
PDF
Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study.
2022 · Stefano Kim, François Ghiringhelli, et al. · Journal of Clinical Oncology · 16
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
2024 · David Tougeron, Laetitia Dahan, et al. · JAMA Oncology · 15
PDF
Works count: 83
Citation count: 3,121
H-index: 21
I10-index: 33
Year
Topic
Type